This is a non-core endpoint: only basic statistics are computed.
Secondary uncertain malignant neoplasm (controls excluding all cancers)
C3_UNCERTAIN_SECONDARY_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters None
0 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints
-
Remove individuals based on genotype QC
3361
C3_UNCERTAIN_SECONDARY_EXALLC
Control definitions
Control exclude
C3_CANCER, C3_CANCER_WIDE
Extra metadata
Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF4
No data for upset plot.
No data for upset table.
Similar endpoints
↥List of similar endpoints to
Secondary uncertain malignant neoplasm (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Secondary uncertain malignant neoplasm
- Malignant neoplasm
- Malignant neoplasm (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
Narrower endpoints:
- Secondary uncertain malignant neoplasm
- Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)
- Secondary and unspecified malignant neoplasm of lymph nodes
- Malignant neoplasm, without specification of site
- Malignant neoplasm, without specification of site (controls excluding all cancers)
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3361 | 1363 | 1998 |
| Unadjusted prevalence (%) | 0.89 | 0.65 | 1.20 |
| Mean age at first event (years) | 61.26 | 57.67 | 63.70 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_UNCERTAIN_SECONDARY_EXALLC – Secondary uncertain malignant neoplasm (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Secondary uncertain malignant neoplasm (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.